From the time of the first haemopoietic stem-cell transplantation (HSCT) for myeloma treatment, controversy about the timing and type of transplant has loomed large. Autologous HSCT is accepted as one legitimate therapy among many, but it is not curative. Fully myeloablative allogeneic HSCT has a reported long-term disease-free survival rate of 22% but an upfront mortality as high as 40%, making it an unappealing option in patients with standard-risk multiple myeloma. Without allogeneic HSCT, 80%...